Healthcare company Viatris Inc (NASDAQ:VTRS) on Wednesday announced positive top-line results from a Phase 3 study of EFFEXOR (venlafaxine) in Japanese adults with generalised anxiety disorder (GAD).
The study demonstrated the efficacy and safety of EFFEXOR in treating GAD, meeting both primary and secondary endpoints and confirming superiority compared to placebo.
Viatris plans to submit the results to the Pharmaceuticals and Medical Devices Agency (PMDA) in 2025.
EFFEXOR is currently approved in Japan for the indication of major depressive disorder in adults. For the indication of GAD, EFFEXOR has been approved in more than 80 countries outside of Japan.
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
BrainCool secures market approval for BrainCool System in Malaysia
Bioretec Ltd secures CE mark approval for RemeOs Trauma Screw portfolio
Biohit launches FAEX Sample System for stool sample collection
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
Innocan Pharma's BI Sky Global completes industry standard safety test
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy